U.S. policy discussions include tariff rates reportedly up to triple digits on certain imported finished drugs. While details are evolving, any broad measure would ripple back to API and KSM sourcing, potentially lifting prices and re-routing orders.
Why it matters for API trade
• Buyers may front‑load Q4 purchases to hedge against cost increases.
• Preference could shift to tariff‑neutral corridors (Mexico, EU, domestic fill‑finish).
• Exporters should prep alternative logistics terms and flexible Incoterms.
